Parexel International Corporation (NASDAQ: PRXL) reiterated to Hold with price target $69 by Deutsche Bank
Deutsche Bank reiterated Parexel International Corporation (NASDAQ: PRXL) to Hold with price target $69 with today's
price of $64.74. Deutsche Bank rated Parexel International Corporation (NASDAQ: PRXL) to Hold with price target $50 on 11/21/2013, when the price was $40.37. Parexel International Corporation's stock price gained 60% since then.
Parexel International Corporation
is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales.
is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank
. This division is one of the largest global asset managers.